Department of Health and Human Services October 19, 2010 – Federal Register Recent Federal Regulation Documents
Results 1 - 16 of 16
Components for Evaluation of Direct-Reading Monitors for Gases and Vapors and Addendum
The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the availability of the following draft publication for public comment. The document and its addendum are entitled, respectively, ``Components for Evaluation of Direct-Reading Monitors for Gases and Vapors'' and ``Addendum to Components for Evaluation of Direct-Reading Monitors for Gases and Vapors: Hazard Detection in First Responder Environments.'' The draft documents and instructions for submitting comments can be found at: https://www.cdc.gov/niosh/docket/ review/docket220. The document expands the 1995 method development and evaluation experimental testing methods to direct-reading monitors for gases and vapors. These Components are provided for laboratory users, consensus standard setting bodies, and manufacturers of direct-reading instrumentation and are compatible with the Instrumentation, Systems, and Automation Society guidelines. The addendum to the document expands the applicability of the Components by presenting methods to be used in evaluating direct-reading monitors for hazard detection in First Responder environments. The 1995 document, entitled ``Guidelines for Air Sampling and Analytical Method Development and Evaluation,'' can be viewed at: https://www.cdc.gov/niosh/docs/ 95-117/. This guidance does not have the force and effect of the law.
Determination That BUSPAR (Buspirone Hydrochloride) Tablets, 10 Milligrams, 15 Milligrams, and 30 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The Food and Drug Administration (FDA) has determined that BUSPAR (buspirone hydrochloride) Tablets, 10 milligrams (mg), 15 mg, and 30 mg, were not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.
National Toxicology Program (NTP); Office of Liaison, Policy and Review Meeting of the NTP Board of Scientific Counselors
Pursuant to Public Law 92-463, notice is hereby given of a meeting of the NTP Board of Scientific Counselors (BSC). The BSC is a federally chartered, external advisory group composed of scientists from the public and private sectors that provides primary scientific oversight to the NTP Director and evaluates the scientific merit of the NTP's intramural and collaborative programs.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
